LIXT Stock Risk & Deep Value Analysis
Lixte Biotechnology Holdings Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About LIXT Stock
We analyzed Lixte Biotechnology Holdings Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran LIXT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is LIXT Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
High
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for LIXT?
- âš
Negative or inconclusive clinical trial results for LB-100
- âš
Failure to secure adequate funding leading to heavy dilution or halting of trials
- âš
Slow patient enrollment in ongoing trials
- âš
Regulatory setbacks or delays
Unlock LIXT Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Lixte Biotechnology Holdings Inc (LIXT) Do?
Market Cap
$25.24M
Sector
Healthcare
Industry
Biotechnology
Employees
2
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Visit Lixte Biotechnology Holdings Inc WebsiteIs LIXT Stock Undervalued?
Unlock the full AI analysis for LIXT
Get the complete DVR score, risk analysis, and more
Does LIXT Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Stable (The potential moat is entirely dependent on clinical success, currently neither expanding nor eroding significantly in the absence of new data).
Moat Sources
1 Identified
The potential for a moat rests entirely on the successful clinical development and regulatory approval of LB-100. If proven safe and effective, the associated patents could provide a temporary competitive advantage. Without clinical validation, the IP has limited practical value.
Moat Erosion Risks
- •Clinical trial failure or inconclusive results
- •Development of superior or similar therapies by competitors
- •Patent challenges or expiry
- •Inability to fund further development to commercialization
LIXT Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive LIXT Stock Higher?
Near-Term (0-6 months)
- •Update on ongoing Phase 1/2 clinical trials for LB-100 (estimated Q2 2026)
- •Potential cash runway extension or minor financing announcement
Medium-Term (6-18 months)
- •Interim data readouts from LB-100 trials in oncology or neurodegeneration (estimated H2 2026 - H1 2027)
- •Potential strategic partnership discussions if early data is compelling
Long-Term (18+ months)
- •Progression of LB-100 to late-stage clinical trials (Phase 2b/3) (estimated 2028+)
- •Breakthrough designation or accelerated approval pathway if efficacy is strong
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for LIXT?
- ✓
Positive Phase 1/2 clinical trial data for LB-100 (especially for efficacy)
- ✓
Announcement of a strategic partnership or non-dilutive licensing deal
- ✓
Successful and less dilutive capital raises extending cash runway beyond 18 months
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for LIXT (Lixte Biotechnology Holdings Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
